TACR2
Substance-K receptor
As of the edition of 20 October 2026, TACR2 (substance-K receptor, UniProt P21452) has 3 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21452
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Mental health; Digestive system; Inherited and neonatal
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Saredutant | Went quiet | Phase 3 | none listed |
| Ibodutant | Stopped | Phase 3 | none listed |
| Nepadutant | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
The other 0 companies at TACR2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at TACR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.